Month: March 2026

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA. “ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce...

VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce that it has filed a technical report (the “Report”) dated January 15, 2026, with an effective date of January 25, 2026, entitled “Technical Report For The Carpenter Lake Property, South Central Athabasca Basin, Northern Saskatchewan, Canada” prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) on the Carpenter Lake Uranium Project (“Carpenter Lake” or the “Project”). The Report was authored by independent Qualified Person Kenneth Wheatley, P. Geo., M.Sc., of Rock U Consulting. The Report is available on SEDAR+ at www.sedarplus.ca and is published on Greenridge’s website at www.greenridge-exploration.com. Statement...

ORLANDO, Fla., March 17, 2026 (GLOBE NEWSWIRE) — Abacus Global Management, Inc. (“Abacus” or the “Company”) (NYSE: ABX), a leader in the alternative asset management industry, today announced its participation in the 38th Annual Roth Conference, taking place at the Ritz-Carlton in Laguna Niguel, CA on March 23-24, 2026. Members of Abacus management, including Chief Financial Officer Bill McCauley, Chief Capital Officer Elena Plesco, and Managing Director of Investor Relations David Jackson will be available for one-on-one and small-group investor meetings throughout the conference. To request a meeting with Abacus management, please contact your Roth representative, or email the Company’s Investor Relations team at ir@abacusgm.com. About AbacusAbacus Global Management (NYSE: ABX) is a leading financial services...

Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States. “The most expensive patient is the one who comes back,” said Michael Feldschuh,...

 Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of Phase 1 clinical study in China by licensee expected in the first half of 2027 HCW Biologics has “free” option to reclaim the rights to the Americas territory MIRAMAR, Fla., March 17, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based commercial- and clinical-stage biopharmaceutical company focused on supporting or developing novel fusion immunotherapies to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced the receipt of full payment of the upfront license fee with a value of $7.0 million from its licensee, Beijing Trimmune Biotech Co., Ltd. (“Trimmune”). Trimmune is...

PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 COG1201 SHIMMER study (NCT05225415) of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the AD/PD™ 2026 Alzheimer’s & Parkinson’s Diseases Conference. The conference is being conducted March 17-21, 2026 in Copenhagen, Denmark. The analysis focuses on Zervimesine’s treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. “In the Phase 2 ‘SHIMMER’ study, we saw a treatment effect across neuropsychiatric, cognitive, motor, and global function domains with zervimesine treatment compared to placebo,” explained Anthony...

Conference Call to Be Held on April 16, 2026 at 2:00pm ET NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the first quarter of 2026 on Wednesday, April 15, 2026 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, April 16, 2026 at 2:00pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Financial Reports”. The live conference call will be webcast in listen-only mode and a replay will be available in the Investors section...